Black Cumin

Clinical Summary

Black cumin (Nigella sativa) is a Ranunculaceae-family seed whose principal bioactive, thymoquinone (TQ), drives broad anti-inflammatory, antioxidant, and metabolic effects. The evidence base is unusually strong for a botanical supplement: a 2025 GRADE-assessed meta-analysis of 82 RCTs (N=5,026) confirmed dose-dependent improvements across body composition, blood pressure, glycemia, lipids, inflammation, liver enzymes, renal markers, and oxidative stress (PMID: 40714301).

Strongest indications: Type 2 diabetes glycemic control, hypertension, dyslipidemia — each backed by multiple meta-analyses totaling thousands of participants. Optimal dose range is 1,000–2,000 mg/day for most cardiometabolic endpoints.

Important nuance: Despite robust glucose-lowering, three independent 2024–2026 meta-analyses found no effect on HOMA-IR or fasting insulin (PMIDs: 41858302, 40210172, 39181437). The glucose-lowering mechanism may be non-insulin-mediated — possibly via reduced hepatic glucose output or enhanced GLUT4 translocation rather than insulin sensitization per se. This is a genuine mechanistic gap.

Key mechanisms: NF-κB pathway inhibition (anti-inflammatory), AMPK activation (metabolic), COX-2/LOX inhibition (pain), antioxidant enzyme upregulation (SOD, CAT, GPx). TQ is metabolized via CYP2C9, CYP2D6, and CYP3A4, with weak inhibitory activity on these enzymes — clinically relevant for narrow-therapeutic-index drugs.

Safety profile: Excellent across 5,026 participants and up to 48 weeks in RCTs. No serious organ toxicity reported. The only pharmacovigilance signal is a serotonin syndrome cluster (6 FAERS suspect reports) likely from MAO-inhibitory activity potentiating serotonergic medications. Wide therapeutic index (therapeutic 1–3g/day; animal LD50 >10g/kg).

Traditional context: Used for 1,400+ years in Middle Eastern and South Asian medicine. The hadith "cure for everything except death" creates cultural hype that sometimes outpaces evidence, particularly for cancer and hair growth claims.

Indications & Evidence

Reading this table: Stars = evidence volume/quality. Type = causal relationship (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7–9=strong causal | 5–6=moderate | 3–4=weak | 1–2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star legend: 5/5 Multiple large RCTs + meta-analyses | 4/5 Several human RCTs | 3/5 Some human pilot/small RCTs | 2/5 Animal or very limited human | 1/5 None/theoretical/debunked

Prescribing

Dosing Table

Formulation Table

Absorption: Take with ≥10g dietary fat for optimal absorption (30–50% higher vs fasted). Half-life 4–6h (TQ); split dosing preferred at >2g/day.

Condition-Specific Protocols

Type 2 Diabetes Protocol

Evidence: 5/5 | PMIDs: 40714301, 41858302, 21675032

Phase 1: Initiation (Weeks 1–2)

• Dose: 1g seed oil/day with breakfast (fatty meal)
• Monitor: Fasting glucose daily; watch for hypoglycemia if on meds
• Goal: Assess GI tolerance

Phase 2: Therapeutic (Weeks 3–12)

• Dose: 2g oil/day split (1g breakfast + 1g dinner, both with fat)
• Monitor: FBS 3×/week, HbA1c at wk 8 + 12, lipid panel at wk 12, weight + BP monthly
• Goal: HbA1c reduction of 0.5–1.0%; FBS reduction of 10–25 mg/dL

Phase 3: Maintenance (Week 12+)

• Dose: 1.5–2g/day based on response
• Monitor: HbA1c q3mo, FBS weekly

Drug Interaction Timing: Metformin — safe to co-administer with meals. Sulfonylureas/insulin — frequent glucose monitoring first 2wk; may need 10–30% medication dose reduction. Expected Outcomes: FBS −18.6 mg/dL (4–6wk), HbA1c −0.56% (8–12wk), LDL −19.5 mg/dL (12wk). No HOMA-IR change expected. Stop/Reassess: Glucose <70 mg/dL → reduce BC dose. No HbA1c improvement by 12wk → non-responder, consider discontinuing.

Hypertension Protocol

Evidence: 5/5 | PMIDs: 40714301, 37341696

• Dose: 2–2.5g oil/day, split AM/PM with meals
• Duration: 8–12wk for maximum effect
• Monitor: Home BP 2×/daily for first 2wk, then weekly
• Expected: SBP −3.25 mmHg, DBP −2.75 mmHg (within 4–8wk)

Drug Interaction Timing: If on ACEi/ARB/CCB — start BC at 1g/day, titrate up over 2wk. Report SBP <90 or symptoms of hypotension to physician. May allow antihypertensive dose reduction.

Hashimoto's Thyroiditis Protocol

Evidence: 3/5 (UCC — single RCT, N=40) | PMID: 27852303

Baseline: TSH, free T3, free T4, TPO antibodies, weight

Treatment:

• Dose: 2g ground seed powder/day, split (1g brunch + 1g dinner)
• CRITICAL: Space 4+ hours from levothyroxine (levothyroxine 6AM fasted → BC 10AM+ with food)
• Duration: Min 8wk for antibody assessment; optimal 12+wk

Monitoring:

• Wk 8: TSH, T3, T4, TPO antibodies, weight
• May need levothyroxine reduction if TSH suppressed (work with endocrinologist)
• Then q8–12wk for thyroid panel, q6mo for antibodies

Expected Outcomes: TPO Ab ↓ 30–55% by 8wk, weight −2.5 kg, TSH normalization in subclinical cases. Fatigue/energy improvement by 8–12wk. Stop/Reassess: Worsening thyroid symptoms → check TSH → discontinue if paradoxical response.

Metabolic Syndrome Protocol

Evidence: 4/5 | PMIDs: 41858302, 38265398

• Dose: 2–3g oil/day split (1.5g breakfast + 1.5g dinner)
• Duration: Min 12wk for comprehensive multi-component effect
• Combine with Mediterranean diet pattern + regular exercise

Multi-Target Monitoring (q12wk): Waist circumference, BP, FBS, lipid panel, CRP. Success = improvement in ≥3 of 5 MetS criteria.

Allergic Rhinitis Protocol

Evidence: 4/5 | PMIDs: 39372205, 39121267

• Dose: 500mg standardized oil (5% TQ) + 2.5mg piperine, BID with food
• Duration: Begin 2wk before allergy season; continue through season (30–60 days)
• Expected: Nasal symptom reduction (congestion, rhinorrhea, sneezing, itching); OR 4.24 vs placebo
• Can combine with standard antihistamines
• Alternative: 2g BSO/day if standardized extract unavailable

Safety

Interactions Table

Contraindications

• Severe bleeding disorders (theoretical antiplatelet effect)
• Pregnancy at therapeutic doses (animal data: uterotonic effects >5× human dose; culinary amounts safe)
• 2 weeks pre-surgery (theoretical bleeding + BP/glucose effects under anesthesia)
• Severe renal impairment (GFR <30): reduce dose 50%, specialist supervision
• Concurrent high-dose serotonergic medications without monitoring

Adverse Effects

FAERS Signal Table (from BioMCP/OpenFDA)

Reading FAERS data: Only the serotonin syndrome cluster (6 reports) has Nigella sativa as suspect drug. All other reports (~190 total across search terms) list it as concomitant with pharmaceutical suspects. This is textbook FAERS noise for supplements not in FDA's drug database.

Monitoring Table

Special Populations

Renal Impairment

Note: Animal data shows nephroprotective effects (TQ via AMPK/PI3K/AKT/mTOR in diabetic nephropathy, PMID: 41757380), but no human renal dosing studies exist. Oxalate content moderate — ensure hydration >2L/day if calcium oxalate stone history.

Hepatic Impairment

Note: Black cumin is hepatoprotective in NAFLD (ALT/AST improved in 82-RCT MA). But hepatoprotective ≠ safe in severe liver failure where metabolism is compromised.

Synergies & Stacking

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Note: No pharmacogenomic studies of Nigella sativa or thymoquinone exist. This is a significant knowledge gap. The above entries are mechanistic inferences, not validated clinical guidance.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Positive across ~2,000+ aggregated reports (Reddit r/Supplements, r/Nootropics, Longecity, WebMD reviews, Islamic wellness forums, biohacker blogs)

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: Low. No major MLM built around BSO (unlike essential oils).
• Influencer concentration: Moderate. Islamic wellness YouTube channels are the largest promotion ecosystem. Dr. Eric Berg and similar channels promote heavily. Generally not extreme.
• Astroturfing signals: Moderate. Brand-specific YouTube comment spam; some Amazon review manipulation suspected.
• Religious marketing: The prophetic medicine heritage (hadith: "cure for everything except death") is historically real but creates overclaiming. Some sellers exploit religious authority for unsubstantiated claims (cancer cure, etc.).
• Quality fraud: HIGH concern. ConsumerLab found 2 of 7 products failed quality testing. Fake certificates of analysis for TQ content documented. Dubai tourist scams ($5,500 losses documented).
• Commercial bias: "Cure-all" framing leads to unrealistic expectations. Most positive reviews come from allergy/inflammation relief, which IS well-supported. Cancer/hair claims are not.

Folk vs Clinical Reality Check

Community experience strongly aligns with clinical data for allergy/respiratory relief, blood sugar control, joint pain, and mood improvement — all supported by RCTs. The GI upset pattern (common initially, resolves) matches trial adverse event profiles exactly. Community experience diverges from clinical data for hair growth (no evidence), grey hair reversal (debunked), weight loss (overestimated), and cancer treatment (preclinical only). The CYP enzyme inhibition reports from harm-reduction communities (Bluelight) deserve clinical attention — thymoquinone's CYP3A4/2D6 inhibition has real pharmacokinetic consequences beyond what most supplement discussions cover.

Deep Dive: Mechanisms & Research

Primary mechanisms with clinical translation:

1. NF-κB inhibition → reduces TNF-α, IL-1β, IL-6, CRP → confirmed in umbrella MA of 7 meta-analyses (PMID: 39709091). Translation: YES — clinical anti-inflammatory effects demonstrated.
2. COX-2 + lipoxygenase inhibition → reduces prostaglandins/leukotrienes → RA/OA symptom relief in RCTs. Translation: YES.
3. AMPK activation → enhanced glucose uptake, GLUT4 translocation → FBS/HbA1c reduction confirmed. BUT HOMA-IR unaffected — mechanism may bypass insulin pathway. Translation: PARTIAL.
4. Calcium channel blocking + NO enhancement → BP reduction confirmed in 82-RCT MA. Translation: YES.
5. HMG-CoA reductase inhibition → lipid reduction confirmed. Translation: YES.
6. Th1/Th2 balance modulation → TPO antibody reduction in Hashimoto's (single RCT). Translation: PRELIMINARY.
7. Antioxidant enzyme upregulation (SOD, CAT, GPx) → MDA/TAC biomarker improvement. Translation: BIOMARKER ONLY — clinical benefit uncertain.

Pharmacokinetics: TQ bioavailability 30–50% (oil with fat). First-pass metabolism via CYP2C9, CYP2D6, CYP3A4. Conjugation with glutathione and glucuronic acid. Excretion primarily urinary (60–70%), fecal (30–40%). Half-life 4–6h. Moderate first-pass effect (~40–60% systemic).

Clinical Trials (from BioMCP / ClinicalTrials.gov)

62+ total registered trials across ClinicalTrials.gov. Dominated by Phase 2 and unspecified-phase studies. Only 1 Phase 4 trial exists. No Phase 3 pivotal trials designed for regulatory approval. Most trial origins: Egypt, Iran, Pakistan, Saudi Arabia, Bangladesh, Iraq, Tunisia, Indonesia.

Regulatory Status (from BioMCP)

• FDA: GRAS food flavoring (21 CFR 182.20). No drug approval. No NDA/ANDA/BLA. DrugBank: DB16447 (thymoquinone), ChEMBL: CHEMBL1672002.
• EMA: No centralized marketing authorization. Some traditional herbal monograph recognition.
• WADA: Not prohibited.
• TGA (Australia): Available as listed complementary medicine ingredient.
• Regulatory context: No pharmaceutical company pursuing drug approval — compound is unpatentable (natural product). This is a commercial viability issue, not a safety signal. The 82-RCT evidence base is stronger than many approved nutraceuticals.

Ataraxia Verdict (as of 2026-04-14)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature: Moderate risk. "Traditional use for 1,400 years" is factual but sometimes used to bypass evidence requirements. Traditional culinary use ≠ evidence for therapeutic doses.
• Hasty generalization: File's original cancer claims extrapolated from animal/in vitro data. SLE claims cited an RCT whose primary endpoint actually failed.
• Appeal to authority: Farhangi (Hashimoto's researcher) cited multiple times — single-lab dependency risk. This finding needs independent replication before 4/5.
• Cherry-picking: Original file claimed "15–25% HOMA-IR improvement" when 3 independent 2024–2026 meta-analyses found NO effect on HOMA-IR. This has been corrected.
• Argument from popularity: "65+ registered trials" is sometimes cited as evidence of quality — but most are Phase 2 or unspecified, with no regulatory-quality pivotal trials.

Evidence Gaps

• HOMA-IR paradox: Lowers glucose and HbA1c but doesn't improve insulin resistance. Why? Possible hepatic glucose output mechanism, but unstudied in humans.
• Zero pharmacogenomic data. No studies on genetic response predictors despite CYP-mediated metabolism.
• No sex-specific PK/PD. Women may clear TQ faster (higher CYP3A4) — untested.
• No long-term safety data >12 months. All RCTs are 4–48 weeks.
• No head-to-head formulation RCTs. Oil vs powder vs extract never directly compared.
• No microbiome data in humans. One pilot (N=8) completed, results not yet published.
• Hair/bone/sleep/longevity: No human evidence for any of these popular claims.

Bias Flags (Mode 4: First Principles)

• Geographic concentration: Overwhelming majority of trials from Middle East/South Asia (Iran, Egypt, Pakistan, Saudi Arabia). Western replication is thin. Cultural familiarity bias may inflate positive publication.
• Industry funding: Most trials are academic. Low commercial bias from supplement industry (no major corporate sponsor). Low pharma counter-bias (no competitor product).
• Publication bias risk: Positive-result bias likely given geographic concentration and small trial sizes. The 82-RCT MA (PMID: 40714301) addresses this with funnel plots but acknowledges heterogeneity.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Moderate. Companies push premium pricing ($40+ for "activation" products). "Prophetic medicine" used as marketing angle in Islamic communities.
• Influencer economics: Islamic wellness YouTube channels + biohacker influencers (Dr. Eric Berg type). Not as concentrated as NMN/longevity influencer ecosystem. Some affiliate-driven content.
• Counter-narrative manipulation: Near zero. No pharma competitor with incentive to fearmonger about black cumin.
• Cui bono summary: PRO: Small supplement companies, Islamic medicine practitioners, MLM-adjacent distributors. ANTI: Essentially nobody. This is actually reassuring — low commercial stakes reduce manipulation incentive.
• Red team highlight: The most concerning angle is quality fraud — ConsumerLab found 2/7 products failed testing. Users may be taking ineffective products and attributing lack of results to the compound rather than the product. This is a supply chain problem, not a compound problem.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 9/10 — one of the most evidence-backed botanical compounds, with broad utility across metabolic (glucose, lipids, BP), anti-inflammatory, and immunomodulatory domains; thymoquinone mechanism is well-characterized and the indication breadth is unusually wide for a botanical.
• Opportunity cost: Very low. ~$8–18/month. 3 capsules/day. Minimal complexity. No significant trade-offs.
• Verdict: ADD — already in stack; evidence supports continued use. One of the most evidence-backed botanical supplements in the vault.
• Conditions: Verify product quality (TQ content 3–5%, third-party tested, dark bottle). Monitor glucose and BP at next lab draw to track personal response.

Bottom Line

Black cumin is a rare botanical supplement that actually delivers on its core claims. The cardiometabolic evidence (BP, glucose, lipids) is backed by 82 RCTs and multiple GRADE-assessed meta-analyses — this is stronger than most prescription nutraceuticals. Safety profile is excellent. The main risks are overgeneralizing to unsupported claims (cancer, hair, cognitive enhancement) and product quality fraud. Continue current stack at 1,350mg/day. Ensure product is cold-pressed, 3–5% TQ, third-party tested. The HOMA-IR paradox is intellectually interesting but doesn't change the clinical recommendation — the glucose/HbA1c reductions are real regardless of mechanism.

Practical Notes

Brands & Product Selection

• Look for cold-pressed, organic, dark glass bottle, 3–5% TQ stated on label, third-party tested (USP, NSF, or CoA)
• Trusted brands (not endorsement): Amazing Herbs (USDA organic, CoA available), Triquetra Health (extensive third-party testing), Heritage Store (mid-range)
• Avoid: Products <$10/100mL (likely adulterated), clear bottles, no TQ standardization, "proprietary blend" without dosage disclosure
• ConsumerLab found 2/7 products failed quality testing — always verify CoA

Storage & Handling

• Oil (opened): Refrigerate immediately (mandatory). Light degrades TQ ~50% in weeks. Use within 6–12mo.
• Oil (unopened): Cool pantry 12–18mo. Dark glass bottle essential.
• Softgels: Room temp, dry, away from heat. 2-year shelf life.
• Seeds (whole): Cool, dry, airtight — 2–3 years. Ground: freeze, use within 1 week.
• Smell test: Fresh = mild peppery/bitter. Rancid = paint/crayon smell → discard (TQ degraded).

Palatability & Compliance

• Oil + honey (equal parts) — traditional method, dramatically masks bitterness
• Berry smoothie (blueberry + banana + honey) — best taste masking
• Capsules bypass taste entirely; DIY: size 00 veggie caps ($10/1000)
• Compliance > optimization: Single daily dose (even if suboptimal) beats split dosing with missed doses
• Habit stack: place bottle next to coffee maker or with lunch supplements

Exercise & Circadian Timing

• Not an ergogenic aid — no evidence for performance enhancement (1/5)
• Post-workout: Theoretical anti-inflammatory benefit; take with post-workout meal if convenient
• Circadian: No strong time-of-day effect. If once daily, take with largest/fattiest meal.
• For hypertension: Evening dose may be slightly superior (nighttime BP dipping pattern)
• For diabetes: Before two largest meals (lunch + dinner) may optimize postprandial glucose control
• Not sleep-disrupting, not sedating — neutral for sleep timing

Reference Ranges (Expected Biomarker Changes)

Cost

• Cold-pressed oil (bulk): ~$0.26/day = $8/mo (best value for evidence-backed form)
• Softgels (mid-range): ~$0.83/day = $25/mo (convenience premium)
• Whole seeds (organic): ~$0.16/day = $5/mo (budget option; must grind fresh)
• 6-month bulk buy saves 30–40%; 12-month often goes rancid before use

Other Practical Notes

• Levothyroxine spacing: Non-negotiable for Hashimoto's. Levothyroxine 6AM fasted → BC 10AM+ with food (4+ hr gap).
• Surgery: Discontinue 2 weeks before elective procedures (theoretical bleeding + BP/glucose effects under anesthesia).
• Withdrawal: None. Can stop abruptly. Effects reverse over 2–4 weeks.
• Travel: Softgels are TSA-friendly. Oil >3.4oz in checked luggage. Seeds may be restricted at some borders.
• Cycling: Not evidence-based (no tolerance documented). Continuous use supported by RCTs up to 48wk. Some community members cycle 8wk on / 2–4wk off as precaution.
• Quality verification sources: Examine.com, ConsumerLab, WHO Monographs Vol. 4 (2009), EMA herbal monograph.

What We Don't Know

• Why it lowers glucose without improving insulin resistance (HOMA-IR paradox)
• Whether genetic variants (CYP2D6, ABCC8/SUR1) predict who responds
• Whether men and women respond differently (no sex-stratified analysis exists)
• Long-term safety beyond 12 months of continuous use
• Whether oil, powder, and standardized extract are bioequivalent
• How it modulates the gut microbiome (one pilot completed, results pending)
• Whether the serotonin syndrome FAERS signal is a real direct effect or purely co-medication confounding
• Optimal TQ dose (most trials don't standardize TQ content; the 2024 allergy RCT using 5% TQ + piperine is a model for future work)
• Whether any cancer benefit translates from preclinical to human (zero human oncology RCTs after 20+ years of in vitro data)
• Effects on hair growth, bone density, sleep quality, eye health, and longevity (no human data for any)

References

Landmark Meta-Analyses (2024–2026)

• Jafari A et al. (2025). GRADE-assessed dose-response MA of 82 RCTs (N=5,026). Pharmacol Res 219:107882. PMID: 40714301
• Musazadeh V et al. (2026). GRADE-assessed cardiometabolic MA, 31 RCTs (N=2,145). Endocrinol Diabetes Metab 9(2):e70207. PMID: 41858302
• Karimi M et al. (2025). Cardiometabolic indices in T2DM, 16 RCTs. Complement Ther Med 90:103174. PMID: 40210172
• Shirvani S et al. (2024). Glycemic status, 30 RCTs. Prostaglandins Other Lipid Mediat 174:106885. PMID: 39181437
• Rounagh M et al. (2024). Lipid profiles, 34 RCTs (N=2,278). Clin Nutr ESPEN 61:168-180. PMID: 38777430
• He Y et al. (2024). Allergic rhinitis, 8 RCTs. Front Pharmacol 15:1417013. PMID: 39372205
• Lan X & Xia Y (2025). Umbrella MA: inflammation + oxidative stress. Prostaglandins Other Lipid Mediat 176:106945. PMID: 39709091
• Kavyani Z et al. (2023). Antihypertensive effects, 22 RCTs (N=1,500+). Phytother Res 37(8):3224-3238. PMID: 37341696
• Kavyani Z et al. (2023). Inflammation/oxidative stress biomarkers. Inflammopharmacology 31(3):1069-1092. PMID: 37036558
• Hallajzadeh J et al. (2020). Metabolic effects, 17 RCTs (N=1,143). Phytother Res 34(10):2586-2608. PMID: 32394508
• Sahebkar A et al. (2016). Blood pressure, 11 RCTs (N=860). J Hypertens 34(11):2127-2135. PMID: 27512975
• Mousavi SM et al. (2018). Obesity indices, 11 RCTs. Complement Ther Med 38:48-57. PMID: 29857882
• Ali M et al. (2024). Endothelial function. Cureus 16(5):e60917. PMID: 38915995
• Shabani M et al. (2024). MetS lipids + glycemic index. Curr Med Chem 31(23):3676-3687. PMID: 38265398
• Saadati S et al. (2022). Prediabetes + T2DM cardiometabolic. Front Nutr 9:1024247. PMID: 36034891

Key RCTs

• Bamosa AO et al. (2010). T2DM glycemic control, N=94. Indian J Physiol Pharmacol 54(4):344-354. PMID: 21675032
• Farhangi MA et al. (2016). Hashimoto's thyroiditis, N=40. BMC Complement Altern Med 16(1):471. PMID: 27852303
• Gheita TA & Kenawy SA (2012). RA, N=40. Phytother Res 26(8):1246-1248. PMID: 22162258
• Gheita TA & Kenawy SA (2012). RA, N=40 (same study as above, single publication). PMID: 22162258
• Nikakhlagh S et al. (2011). Allergic rhinitis. Am J Otolaryngol 32(5):402-407. PMID: 20947211
• Boskabady MH et al. (2007). Asthma. Fundam Clin Pharmacol 21(5):559-566. PMID: 17868210
• Darand M et al. (2019). NAFLD. Complement Ther Med 44:204-209. PMID: 31126557
• Bin Sayeed MS et al. (2013). Cognition/MCI. J Ethnopharmacol 148(3):780-786. PMID: 23707331
• Majeed A et al. (2024). Seasonal allergy, 5% TQ + piperine, N=65. Medicine 103(32):e39243. PMID: 39121267
• Barlianto W et al. (2024). Pediatric SLE, N=32. Narra J 4(3):e1063. PMID: 39816053
• El-Afify D & El Amrousy D (2025). Pediatric T1DM cardioprotection, N=60. Paediatr Drugs 27(4):481-489. PMID: 40048139
• Afrin F et al. (2025). PMS severity, double-blind RCT. Biomed Res Int 2025:9811666. PMID: 41267796
• Razmpoosh E et al. (2024). IL-1β/IL-6/leptin in obese women, crossover RCT, N=46. BMC Complement Med Ther 24(1):22. PMID: 38178093
• Bakir E & Baglama SS (2026). Knee OA + black cumin oil massage, N=150. Holist Nurs Pract 40(1):56-65. PMID: 39642267
• Arab Farashahi M et al. (2026). Gingivitis vs chlorhexidine, N=36. J Integr Complement Med 32(3):277-283. PMID: 41472641
• Kooshki A et al. (2016). CVD risk in T2DM. Phytother Res 30(12):2003-2008. PMID: 27640904
• Datau EA et al. (2010). Testosterone in obese men, N=25. Acta Med Indones 42(3):130-134. PMID: 20724766
• Farhangi MA et al. (2018). Oxidative DNA damage in obese women, N=44. Phytomedicine 42:232-239. PMID: 29655726
• Kalus U et al. (2003). Allergic diseases. Phytother Res 17(10):1209-1214. PMID: 14669258

Safety & Mechanism

• Pelegrin S et al. (2019). Safety review. Phytother Res 33(10):2518-2540. PMID: 31321819
• Phase I safety trial: TQ-rich BSO. PMID: 36518481
• Contact allergen case report. PMID: 32232855
• Tavakkoli A et al. (2017). Clinical trials review, 37 trials. J Pharmacopuncture 20(3):179-193. PMID: 31288139
• Darakhshan S et al. (2015). TQ mechanisms. Pharmacol Res 95-96:138-158. PMID: 25829334
• Woo CC et al. (2012). TQ anti-inflammatory/cancer mechanisms. Biochem Pharmacol 83(4):443-451. PMID: 21763686
• Yimer EM et al. (2019). Comprehensive review. Evid Based Complement Alternat Med 2019:1528635. PMID: 31118980
• Daryabeygi-Khotbehsara R et al. (2017). T2DM glucose + lipids MA. Complement Ther Med 35:6-13. PMID: 29154054
• Qodir N et al. (2025). TQ + chemo for breast cancer (preclinical SR). J Clin Med Res 17(5):270-284. PMID: 40503065
• Mostafa MD et al. (2026). TQ neuroprotection in obesity. Metab Brain Dis 41(1). PMID: 41920373
• Adnan M et al. (2026). ABCC8/SUR1 as TQ target (multi-omics). Chem Biol Drug Des. PMID: 41896712